Skip to main content

Calcium, Vitamin D Supplements May Reduce Cancer Mortality in Long Term

Medically reviewed by Carmen Pope, BPharm. Last updated on March 12, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, March 11, 2024 -- For postmenopausal women, calcium and vitamin D (CaD) supplements may reduce cancer mortality and increase cardiovascular disease (CVD) mortality after more than 20 years of follow-up, according to a study published online March 12 in the Annals of Internal Medicine.

Cynthia A. Thomson, Ph.D., R.D., from the Mel and Enid Zuckerman College of Public Health at the University of Arizona in Tucson, and colleagues examined long-term health outcomes among postmenopausal women in the Women's Health Initiative CaD trial involving 36,282 women with no history of breast or colorectal cancer. Participants were randomly assigned to receive 1,000 mg calcium carbonate with 400 IU vitamin D3 daily or placebo.

The researchers found that after a median cumulative follow-up of 22.3 years, women randomly assigned to CaD versus placebo had a reduction in cancer mortality (hazard ratio, 0.93), and an increase in CVD mortality (hazard ratio, 1.06). No overall effect was seen on other measures, including all-cause mortality. There was considerable variation observed in estimates of cancer incidence when stratified by whether participants reported supplement use before randomization, while no variation was seen for estimates in mortality, except for CVD mortality.

"Effects of vitamin D supplementation for cancer prevention may depend on achieving serum vitamin D concentrations above 50 nmol/L," the authors write. "Given the study design, we could not disentangle the added benefit or harms of supplementation with CaD in combination versus vitamin D alone, a topic worthy of future study."

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted March 2024

Read this next

ASCO: Conjugated Equine Estrogen May Increase Risk for Ovarian Cancer

TUESDAY, May 28, 2024 -- Conjugated equine estrogen (CEE) taken alone for menopause may increase the risk for developing and dying from ovarian cancer, according to a study...

Fezolinetant Safe, Effective for Moderate-to-Severe Menopause Hot Flashes

MONDAY, May 20, 2024 -- Fezolinetant is safe and effective for moderate-to-severe vasomotor symptoms (VMS), according to a study presented at the annual European Congress of...

Risk for Depressive Symptoms Increased for Perimenopausal Women

THURSDAY, May 9, 2024 -- Perimenopausal women have an increased risk for depressive symptoms and diagnoses, according to a review published in the July 15 issue of the Journal of...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.